<DOC>
	<DOCNO>NCT01965275</DOCNO>
	<brief_summary>purpose study evaluate efficacy safety high-dose，pulsatile Erlotinib/Gefitinib advance non small cell lung cancer ( NSCLC ) patient failure standard dose EGFR-TKIs（Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors）</brief_summary>
	<brief_title>High-Dose , Pulsatile Erlotinib/Gefitinib Advanced NSCLC Patients After Failure Standard Dose EGFR-TKIs</brief_title>
	<detailed_description>To evaluate efficacy safety treat advanced non small cell lung cancer ( NSCLC ) patient failure standard dose EGFR-TKIs ( Erlotinib Gefitinib ) high-dose , pulsatile Erlotinib ( 450mg every 3 day ) Gefitinib ( 1000mg every 4 day )</detailed_description>
	<mesh_term>Drug-Related Side Effects Adverse Reactions</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>1 . NSCLC patient confirm histology cytology 2 . Patients ever treat standard dose EGFRTKIs ( Erlotinib Gefitinib ) he/she achieve complete remission/partial remission , maintain stable disease 4 months.Disease progression present ( accord RECISTv1.1 criteria） 3.At least one target lesion previously radiate measurable accord RECIST v1.1 ; 4.Have ECOG PS 02 5.At least 8 week expect survival time 6.Have serious cardiovascular , hepatobiliary renal disorder 7.Provision voluntarily give , personally sign date , write informed consent document 8.Must accordance follow laboratory biochemical data : Hgb≥80g/L，WBC≥3.0×10^9/L，ANC≥1.0×10^9/L， PLT≥80×10^9/L Renal function：SCr≤ULN Liver function： hepatic metastasis : AST/ALT≤2.5ULN hepatic metastasis : AST/ALT≤5ULN If subject meet follow exclusion criterion , he/she eligible participate study 1 . Have chronic toxicity reaction ( grade 2 ) recover ( hair loss include ) 2 . Have Appeared skin rash diarrhea ( grade 3 ) , reason lead decrement standard dose EGFRTKIs treatment 3 . Female subject pregnancy lactation，or childbearing age n't take contraceptive measure 4 . Current enrollment another therapeutic clinical study 5 . Have symptom brain metastasis leptomeningeal metastases 6 . Subjects eligible history prior malignancy past 5 year 7 . Any psychiatric cognitive disorder would limit understand render informed consent and/or compromise compliance requirement study know drug abuse/alcohol abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Advanced non-small cell lung cancer</keyword>
	<keyword>High-dose</keyword>
	<keyword>Pulsatile</keyword>
	<keyword>EGFR-TKIs</keyword>
</DOC>